Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastrointestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain and analgesics, respiratory, and vitamins, minerals, and nutrients; and contract development services. The company was incorporated in 1978 and is headquartered in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Revenue projections:

Revenue projections for GLAND
Revenue projections for GLAND

Gland Pharma Limited's revenues are expected to fall below last year's, and this forecast tends to raise concerns among investors. A revenue drop can negatively impact the company's profitability, making investors more cautious about their positions due to the risks of declining financial performance.

Financial Ratios:

currentRatio 4.335000
forwardPE 26.464287
debtToEquity 3.428000
earningsGrowth -0.031000
revenueGrowth -0.073000
grossMargins 0.592360
operatingMargins 0.176680
trailingEps 42.440000
forwardEps 65.010000

GLAND's current ratio, being 4.335, demonstrates that the company has the liquidity necessary to service its short-term debt. With strong cash reserves and current assets, GLAND is well-equipped to meet its immediate financial obligations without any difficulties.
Gland Pharma Limited's Forward PE is in an attractive range, meaning its stock price aligns well with earnings and isn't inflated. This creates room for growth, making it a solid investment opportunity for those looking to benefit from potential price appreciation.
GLAND's low earnings and revenue growth highlight potential profit shrinkage. This suggests that the company may struggle to maintain its financial performance, raising concerns about its future profitability.
GLAND's negative gross and operating margins signal that the company is not profitable, struggling to cover costs associated with production and operations. This could be a red flag for its financial performance moving forward.
With a forward EPS greater than its trailing EPS, Gland Pharma Limited is forecasted to be more profitable this year than last. This growth expectation reflects confidence in the company's earnings potential and suggests an improving financial trajectory for the year ahead.

Price projections:

Price projections for GLAND
Price projections for GLAND

Price projections for GLAND have been steadily revised downward over time, indicating growing concerns about the company's future performance. This downward trend reflects reduced optimism among analysts regarding GLAND's ability to meet previous expectations.

Insider Transactions:

Insider Transactions for GLAND
Insider Transactions for GLAND


GLAND saw 9 transactions in which shares were sold with market price at 1839.5444471571182.No sell transactions were carried out during the period under review.Investors are purchasing Gland Pharma Limited more frequently than selling it near the current price levels, which might point to a bullish sentiment. This pattern could be interpreted as a favorable outlook for the stock's future.

Recommendation changes over time:

Recommendations trend for GLAND
Recommendations trend for GLAND


The recent sell bias from analysts on GLAND suggests investors should be cautious. However, it's a good idea to base decisions on a broader range of market indicators to gain a more complete and accurate view of the stock's potential performance in the near term.